Phase II study of volociximab (M200), an alpha 5 beta 1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC) Meeting Abstract

  

Authors:	Figlin, R. A.; Kondagunta, G. V.; Yazji, S.; Motzer, R. J.; Bukowski, R. M.
Abstract Title:	Phase II study of volociximab (M200), an alpha 5 beta 1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)
Meeting Title:	42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	24
Issue:	18 Suppl. Pt. 1
Meeting Dates:	2006 Jun 2-6
Meeting Location:	Atlanta, GA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2006-06-01
Start Page:	225S
Language:	English
ACCESSION:	WOS:000239009401334
PROVIDER:	wos
DOI:	10.1200/jco.2006.24.18_suppl.4535
Notes:	--- - Meeting Abstract: 4535 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology - JUN 02-06, 2006 - Atlanta, GA - S - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/32253